The fusion of mRNA technology with AI has laid the foundation for ushering in a new era of cancer care. However, conducting ...

Goldman has recently reduced Moderna Inc (MRNA) stock to Neutral rating, as announced on January 29, 2025, according to Finviz. Earlier, on December 18, 2024, Argus had reduced the stock from a Buy to ...

A US-based pharmaceutical company known for its revolutionary mRNA technology, has completed construction of its Moderna Innovation and Technology Centre (MITC) at Harwell in Oxfordshire.

A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

The following first ran on CounterPunch at the height of the COVID pandemic in January of 2022. Are anti-vaccine ...

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to ...

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...